Alnylam Pharmaceuticals, Inc. (ALNY) Posts Wider than Expected Q2 Loss
Tweet Send to a FriendGet Alerts ALNY Hot Sheet
Price: $29.99 --0%
EPS Growth %: +40.0%
Financial Fact:
Research and development: 22.18M
Today's EPS Names:
CRWS, CLC, FNSR, More
EPS Growth %: +40.0%
Financial Fact:
Research and development: 22.18M
Today's EPS Names:
CRWS, CLC, FNSR, More
Trade ALNY Now!
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.81 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Five Below (FIVE) Tops Q1 EPS by 1c, Boosts FY13 Outlook
- Linktone Ltd. (LTON) Q1 Profit Slips to 10c/ADS
- PVH Corp. (PVH) Tops Q1 EPS by 56c; Issues Q2 EPS, Revs Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
